Cargando…
Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review
BACKGROUND: Dual anti-human epidermal growth factor receptor 2 (HER2) therapies have been shown to improve outcomes of HER2-positive breast cancer patients. We undertook a systematic review to compare treatment outcomes for patients who received single or combined anti-HER2 therapies. METHODS: We id...
Autores principales: | Zhang, Xiao, Zhang, Xin-Ji, Zhang, Tian-Yi, Yu, Fei-Fei, Wei, Xin, Li, Ye-Sheng, He, Jia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161893/ https://www.ncbi.nlm.nih.gov/pubmed/25164542 http://dx.doi.org/10.1186/1471-2407-14-625 |
Ejemplares similares
-
Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report
por: Guan, Ji-Lin, et al.
Publicado: (2020) -
Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report
por: Yue, Li, et al.
Publicado: (2020) -
The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer
por: Li, Guo-Cai, et al.
Publicado: (2020) -
Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
por: Xie, Jindong, et al.
Publicado: (2022) -
Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2020)